Search research articles
Contact Us
Filters
Showing results (81-90 of 124) with videos related to
Page
of 13
Sort By:
The Lancet. Oncology
|
August 18, 2018
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
Martin J van den Bent, Martin Klein, Marion Smits, et al.
Journal of Neuro-Oncology
|
July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma
Andrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.
Neuro-Oncology Advances
|
July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
Youri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2012
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, et al.
Neuro-Oncology
|
August 16, 2022
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas
Mark P van Opijnen, C Mircea S Tesileanu, Linda Dirven, et al.
Science Advances
|
May 6, 2021
SMARCAD1-mediated active replication fork stability maintains genome integrity
Calvin Shun Yu Lo, Marvin van Toorn, Vincent Gaggioli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2019
Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma, Aikaterini Chatzipli, Martin Taphoorn, et al.
Cancer Research
|
January 15, 2016
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
Lale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Kaspar Draaisma, C Mircea S Tesileanu, Iris de Heer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
Andrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 124) with videos related to
Sort By:
Page
of 13
The Lancet. Oncology
|
August 18, 2018
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
Martin J van den Bent, Martin Klein, Marion Smits, et al.
Journal of Neuro-Oncology
|
July 6, 2019
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma
Andrew B Lassman, Kenneth D Aldape, Peter J Ansell, et al.
Neuro-Oncology Advances
|
July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
Youri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2012
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, et al.
Neuro-Oncology
|
August 16, 2022
IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas
Mark P van Opijnen, C Mircea S Tesileanu, Linda Dirven, et al.
Science Advances
|
May 6, 2021
SMARCAD1-mediated active replication fork stability maintains genome integrity
Calvin Shun Yu Lo, Marvin van Toorn, Vincent Gaggioli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 20, 2019
Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma, Aikaterini Chatzipli, Martin Taphoorn, et al.
Cancer Research
|
January 15, 2016
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
Lale Erdem-Eraslan, Martin J van den Bent, Youri Hoogstrate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
Kaspar Draaisma, C Mircea S Tesileanu, Iris de Heer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
Andrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.
Page
of 13